Ovarian Hyperstimulation Syndrome
Conditions
Keywords
letrozole, ovarian hyperstimulating syndrome
Brief summary
Letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. In 2009, Letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.
Detailed description
Letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. In this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.
Interventions
DRUGletrozole
letrozole from the day of oocyte retrieval for 5 days
DRUGAspirin
aspirin from the day of oocyte retrieval for 5 days
Sponsors
First Affiliated Hospital, Sun Yat-Sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* infertile women undergoing IVF treatment with more than 25 oocytes collected.
Exclusion criteria
* letrozole contraindications,e.g. severe hepatic and renal dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of early OHSS | up to 1 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence of hydrothorax | up to 1 months | — |
| incidence of liver dysfunction | up to 1 months | — |
| incidence of renal dysfunction | up to 1 months | — |
| vascular endothelial growth factor level | up to 1 months | vascular endothelial growth factor in pg/ml |
| incidence of hemoconcentration | up to 1 months | — |
| incidence of elevated WBC | up to 1 months | — |
| incidence of electrolytic imbalance | up to 1 months | — |
Outcome results
None listed